Warning: The NCBI web site requires JavaScript to function. more...
The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model.
Lai MD, Yen MC, Lin CM, Tu CF, Wang CC, Lin PS, Yang HJ, Lin CC.
Genet Vaccines Ther. 2009 Jan 30;7:2.
Related citations
Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.
Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B, Kan B, Wen YJ, Liu F, Deng HX, Li J, Mao YQ, Lei S, Huang MJ, Peng F, Jiang Y, Zhou H, Zhou LQ, Luo F.
J Immunol. 2003 Mar 15;170(6):3162-70.
[Novel vaccines against M. tuberculosis].
Okada M.
Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.
Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor.
Hu B, Wei Y, Tian L, Zhao X, Lu Y, Wu Y, Yao B, Liu J, Niu T, Wen Y, He Q, Su J, Huang M, Lou Y, Luo Y, Kan B.
J Immunother. 2005 May-Jun;28(3):236-44.
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Shimoyama T, Koizumi F, Fukumoto H, Kiura K, Tanimoto M, Saijo N, Nishio K.
Lung Cancer. 2006 Jul;53(1):13-21. Epub 2006 May 19.
Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route.
Tu CF, Lin CC, Chen MC, Ko TM, Lin CM, Wang YC, Lai MD.
Vaccine. 2007 Jan 8;25(4):719-28. Epub 2006 Aug 22.
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
Cancer Res. 2004 Jul 15;64(14):4931-41.
Human T lymphocyte responses against lung cancer induced by recombinant truncated mouse EGFR.
Hu B, Wei YQ, Tian L, Zhao X, Lu Y, Wu Y, Yao B, Zhang XW.
Cancer Immunol Immunother. 2006 Apr;55(4):386-93. Epub 2005 Oct 19.
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
Cancer Res. 2004 Aug 1;64(15):5355-62.
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.
Clin Cancer Res. 2006 Dec 1;12(23):7117-25.
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.
Clin Cancer Res. 2004 Jan 15;10(2):784-93.
Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu.
Lin CC, Chou CW, Shiau AL, Tu CF, Ko TM, Chen YL, Yang BC, Tao MH, Lai MD.
Mol Ther. 2004 Aug;10(2):290-301.
Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR.
Clin Cancer Res. 2004 Jul 15;10(14):4874-84.
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, Kang CY.
Cancer Res. 2007 Aug 1;67(15):7477-86.
Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.
McCluskie MJ, Brazolot Millan CL, Gramzinski RA, Robinson HL, Santoro JC, Fuller JT, Widera G, Haynes JR, Purcell RH, Davis HL.
Mol Med. 1999 May;5(5):287-300.
Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, Lubet RA, You M.
Mol Cancer Res. 2006 Dec;4(12):971-81.
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS.
Mol Cancer Ther. 2007 Oct;6(10):2652-63. Epub 2007 Oct 3.
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
Clin Cancer Res. 2004 Oct 1;10(19):6487-501.
[Immunotherapeutic effect of recombinant EGFR phage vaccine on tumors].
Liu D, Tang L, Zhou CC, Tan LS.
Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):728-32. Chinese.
Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2.
Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F, Liu JY, Yang JL, Lou YY, Hu B, Niu T, Wen YJ, Xiao F, Deng HX, Li J, Kan B.
Cancer Res. 2003 Feb 1;63(3):600-7.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on